Lantibio, a drug development firm focused on treatment of ocular disease and serious respiratory conditions, has licensed a potential treatment for dry eye from a European firm.
Lantibio struck the deal with TRB Chemedica for the drug Vismed. It is currently marketed in Europe by TRB. TRB is based in Switzerland.
Lantibio said it hopes to commence clinical studies this year.